Platelet hypersensitivity to serotonin after prolonged ketanserin intake?

Area of Science:

• Pharmacology
• Hematology
• Cardiovascular Research

Background:

• Platelet aggregation plays a crucial role in hemostasis and thrombosis.
• Serotonin (5-HT) is a potent stimulator of platelet aggregation.
• Ketanserin is a known serotonin receptor antagonist with antiplatelet properties.

Purpose of the Study:

• To investigate the acute and short-term effects of ketanserin on serotonin-induced platelet aggregation in healthy volunteers.
• To determine the temporal dynamics of ketanserin's impact on platelet responsiveness.
• To explore the potential development of altered platelet sensitivity to serotonin with ketanserin treatment.

Main Methods:

• Eight healthy volunteers participated in the study.
• Ketanserin was administered at 40 mg three times daily for one week.
• Blood samples were collected at specific time points to measure serotonin-induced platelet aggregation rates.

Main Results:

• Acute ketanserin administration significantly decreased the maximal rate of serotonin-induced platelet aggregation.
• A delayed hyperresponsiveness to serotonin was observed after 7 days of ketanserin treatment.
• The final dose of ketanserin normalized the hyperresponsiveness, indicating temporary correction.
• In vitro studies suggested increased platelet sensitivity to serotonin rather than refractoriness to ketanserin with prolonged use.

Conclusions:

• Ketanserin exhibits a biphasic effect on platelet aggregation: initial inhibition followed by delayed potentiation.
• Prolonged ketanserin intake may lead to increased platelet sensitivity to serotonin.
• Further research is warranted to understand the clinical implications of these findings.